Table 3.
Bispecific antibodies currently tested in clinical trials in AML.
| Name of Agent | Type of Agent | Target | Effector * | Phase | NCT |
|---|---|---|---|---|---|
| AMG330 | BiTE | CD33 | CD3 | I | NCT02520427 |
| AMG673 | BiTE | CD33 | CD3 | I | NCT03224819 |
| AMV564 | Tandem diabody | CD33 | CD3 | I | NCT03144245 |
| GEM333 | Single-chain diabody | CD33 | CD3 | I | NCT03516760 |
| 161533 ** | TriKE | CD33 | CD16 | I/II | NCT03214666 |
| MGD006 (flotetuzumab) | DART | CD123 | CD3 | I | NCT02152956 |
| JNJ-63709178 | DuoBody | CD123 | CD3 | I | NCT02715011 |
| XmAb14045 | X-mAb *** | CD123 | CD3 | I | NCT02730312 |
| MCLA-117 | Biclonics **** | CD371 | CD3 | I | NCT03038230 |
* Effector: Targeted molecule on the effector cells. ** 161533 is a CD33 x CD16 TriKE that contains an interleukin-15 (IL-15) cross-linker and thereby is considered to augment NK cell expansion and function and to correct NK cell dysfunction in AML. *** X-mAb are antibody constructs that include a bispecific Fc domain that serves as a scaffold for the two antigen-binding domains. **** Bispecific antibody that binds to CD3 to recruit T cells. Abbreviations: AML, acute myeloid leukemia; NCT, national clinical trial identifier; BiTE, bispecific T cell engagers; TriKE, tri-specific killer engager; DART, dual affinity retargeting antibody.